Ion Resonance
SEQEX AND ION RESONANCE
The Seqex® system was developed based on research conducted in the mid 1970s by the scientist W.R. Adey, who discovered that it is possible to stimulate the biological ions in living organisms using extremely low frequency and low intensity electromagnetic fields.
Over the following years, Carl Blackman, a scientist at the U.S. EPA (Environmental Protection Agency), discovered that these results were critically dependent on the direction of application of the electromagnetic fields.
In 1984 Prof. A.R. Liboff, interested at the time in the biological effects of cosmic radiation, hypothesized that the discoveries of Adey and Blackman could easily be explained by assuming that the terrestrial magnetic field, or geomagnetic field (GMF), interacted with the applied variable fields, producing a phenomenon known as ion cyclotron resonance (ICR) directly inside tissues.
The phenomenon of ICR is well known to physics: it requires the simultaneous application of two parallel magnetic fields, one static and one variable through time.
Assuming that the effects observed in the laboratory by Adey and Blackburn were caused by ICR, Liboff demonstrated that, on the basis of the frequencies used and the values of the GMF, the range of intensity of the GMF on the Earth’s surface corresponded with ICR frequencies, so that very low physiologically significant frequencies were capable of affecting key biological ions, like for example calcium, potassium, and magnesium.
These discoveries were of revolutionary importance: the observations of Adey and Blackman had effectively revealed an intrinsic electromagnetic property in living beings.
Liboff further demonstrated that the previous successes with pulsed magnetic fields (PMF, also known as magnetotherapy) for treatment of bone diseases like arthrosis, osteoporosis, and delayed consolidation presented by Dr. C.A.L. Bassett in the 1970s were very probably specific cases of ICR. These known physical effects were therefore derived from the probability of the wide frequency band of the PFM signals also including ICR frequencies.
In order to verify these hypotheses Liboff, with the help of Prof. S.D. Smith, Prof. B.R. McLeod, Dr. J. Thomas, and the undergraduate K. A. Jenrow, undertook a long series of experiments that proved beyond all doubt that combinations of ICR from magnetic fields tuned to certain ions can have profound effects on living beings, be these cell cultures or complete organisms.
In 1987 the U.S. FDA (Food and Drug Administration) authorized the first medical application of ICR to treat delayed consolidation of bone fractures, and a few years later a second medical application was approved to assist spinal fusion (in cases of spina bifida). These treatments were administered locally in the area of the lesions or symptoms. To date these applications of ICR generate an annual worldwide business of around 85 million dollars.
